CytomX Announces Management Team Promotions

SOUTH SAN FRANCISCO, Calif., Aug. 3, 2015 /PRNewswire/ -- CytomX, a biopharmaceutical company developing Probody therapeutics for the treatment of cancer, today announced the promotion of several members of its leadership team.

Debanjan Ray, who previously served as vice president of business development and alliance management, has been promoted to senior vice president of corporate development and strategy. Prior to joining CytomX, Mr. Ray held positions as the vice president of business development at Itero Biopharmaceuticals and as associate director of business development at Portola Pharmaceuticals.

Bryan Irving, Ph.D., who previously served as senior director of cancer immunology, has been promoted to vice president of cancer immunology. Prior to joining CytomX, Dr. Irving conducted research at Genentech that resulted in the anti-PD-L1 antibody, atezolizumab, currently in clinical development, and held positions in academia where he conducted influential research into the single-chain chimeric antigen receptor (CAR) technology now being used in patients' T cells to treat hematologic malignancies.

Jon Terrett, Ph.D., who previously served as senior director of oncology, has been promoted to vice president of oncology discovery. Prior to joining CytomX, Dr. Terrett was chief scientific officer of Oxford BioTherapeutics and served as a director for each of Medarex, CellTech and Oxford GlycoSciences.

Carol Talkington Verser, Ph.D., who previously served as senior director of intellectual property, has been promoted to vice president of intellectual property. Prior to joining CytomX, Dr. Verser held positions as executive vice president, intellectual property and business development, at Heska Corporation and as patent agent and technical specialist at Sheridan Ross.    

"We are committed to the development and advancement of our team at every level and these senior promotions are illustrative of our commitment to building a great company around great people," said Sean McCarthy, D.Phil, chief executive officer of CytomX. "I look forward to continuing to work closely with Debanjan, Bryan, Carol and Jon as we continue to pursue our vision of transforming lives with safer, more effective therapies."

About CytomX Therapeutics 
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on its Probody technology platform. The company uses the platform to create proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class cancer therapeutics against novel targets. CytomX believes that its Probody platform will improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and T-cell-recruiting bispecific antibodies. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. Probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, such as CD-166, that are difficult to drug and lead to damage to healthy tissues, or toxicities. In addition to its proprietary programs, CytomX is collaborating with strategic partners including Bristol-Myers Squibb Company, Pfizer Inc. and ImmunoGen, Inc. For more information, visit www.cytomx.com.  

Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause the actual results performance or achievements to be materially different  from any future results, performance or achievements expressed or implied in such statements. Because forward-looking statements are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, many of which are beyond CytomX's control, you should not rely on any of these forward-looking statements. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

Media Contacts: 
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388

Investor Contacts:
Trout Group
Pete Rahmer
prahmer@troutgroup.com 
646-378-2973

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytomx-announces-management-team-promotions-300122325.html

SOURCE CytomX Therapeutics